XLRN News and Press, Acceleron Pharma Inc. From 02/27/19

The following slide deck was published by Acceleron Pharma Inc. in conjunction with their 2018 Q4 earnings Read more ...

Acceleron Pharma (NASDAQ: XLRN ): Q4 GAAP EPS of -$0.75 misses by $0.07 . More news on: Acceleron Pharma Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

- MEDALIST and BELIEVE Phase 3 trial presentations at the 60 th American Society of Hematology (ASH) Annual Meeting both selected for “Best of ASH” - - Luspatercept Biologics License Application (BLA) submission expected in April 2019 - - Part 2 results from the...

AEGN , ALEX , AMED , ANSS , APA , ATSG , AYX , BEL , BGNE , BILI , BKNG , BOLD , BOX , CABO , CCRN , CHDN , COLL , CRC , CVNA , CWK , DAR , ECPG , ERI , ESTC , ESV , FG , FIT , FOE , FTAI , FTSI , GEF , GKOS , HGV , HHC , HPQ , ITRI , KRA , KW , LADR ,...

Acceleron Pharma (NASDAQ: XLRN ) is scheduled to announce Q4 earnings results on Wednesday, February 27th, after market close. The consensus EPS Estimate is -$0.68 (-9.7% Y/Y) and the consensus Revenue Estimate is $3.04M (-18.1% Y/Y). Over the last 2 years, XLRN has beaten EPS estimat...

Acceleron Pharma (NASDAQ: XLRN ) initiated with Outperform rating and $78 (84% upside) price target at Cowen and Company. More news on: Acceleron Pharma Inc., EXACT Sciences Corporation, Kadmon Holdings, Healthcare stocks news, Stocks on the move, , Read more ...

Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Wednesday, February 27, 2019 at 5:00 p.m. EST to discuss its fourth quarter and full year 2018 operating and financial results. The webcast will be accessible under "Events & Presentatio...

Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics intended to treat serious and rare diseases, today announced that senior management will present at two upcoming healthcare investor conferences. ...